ACADIA Pharmaceuticals
ACAD
#3233
Rank
C$7.09 B
Marketcap
C$41.44
Share price
1.17%
Change (1 day)
21.23%
Change (1 year)

P/E ratio for ACADIA Pharmaceuticals (ACAD)

P/E ratio as of August 2026 (TTM): 13.2

According to ACADIA Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 13.1794. At the end of 2025 the company had a P/E ratio of 11.5.

P/E ratio history for ACADIA Pharmaceuticals from 2004 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202511.5-14.67%
202413.5-116.38%
2023-82.4593.52%
2022-11.9-46.55%
2021-22.2-25.16%
2020-29.711.08%
2019-26.7222.44%
2018-8.29-35.28%
2017-12.83.96%
2016-12.3-43.65%
2015-21.9-35.25%
2014-33.8
2012-12.6

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
30.0 127.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
20.6 56.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
43.6 231.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
18.2 38.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Vanda Pharmaceuticals
VNDA
-1.24-109.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Adamas Pharmaceuticals
ADMS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.